Trial Profile
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUME-Colon 1
- Sponsors Boehringer Ingelheim; Unilfarma
- 13 Jul 2018 Results published in the Annals of Oncology
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
- 21 Jan 2017 Results of prespecified subanalysis presented at the 2017 Gastrointestinal Cancers Symposium